Press coverage about Cellular Biomedicine Gr (NASDAQ:CBMG) has trended somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellular Biomedicine Gr earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.522085481677 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
A number of equities research analysts recently weighed in on the stock. Maxim Group cut shares of Cellular Biomedicine Gr from a “buy” rating to a “hold” rating in a research note on Thursday, February 1st. B. Riley restated a “buy” rating on shares of Cellular Biomedicine Gr in a research note on Friday, March 16th. ValuEngine upgraded shares of Cellular Biomedicine Gr from a “sell” rating to a “hold” rating in a research note on Wednesday, April 4th. Finally, BidaskClub upgraded shares of Cellular Biomedicine Gr from a “hold” rating to a “buy” rating in a research note on Wednesday, January 10th.
Shares of NASDAQ CBMG opened at $20.50 on Monday. Cellular Biomedicine Gr has a fifty-two week low of $5.05 and a fifty-two week high of $22.75. The stock has a market cap of $357.80, a P/E ratio of -11.52 and a beta of 3.47.
In related news, Director Wen Tao Liu sold 10,400 shares of Cellular Biomedicine Gr stock in a transaction dated Tuesday, April 10th. The shares were sold at an average price of $20.10, for a total transaction of $209,040.00. Following the sale, the director now directly owns 223,476 shares in the company, valued at $4,491,867.60. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 8.30% of the stock is owned by insiders.
Cellular Biomedicine Gr Company Profile
Cellular Biomedicine Group, Inc, a clinical stage biopharmaceutical company, develops therapies for cancer and degenerative diseases in Greater China. It focuses on developing and marketing cell-based therapies to treat various diseases, such as cancer, orthopedic, and metabolic diseases. The company develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; tumor cell specific dendritic cell therapy; and Re-Join therapy and AlloJoin therapy for the treatment of knee osteoarthritis.
Receive News & Ratings for Cellular Biomedicine Gr Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Gr and related companies with MarketBeat.com's FREE daily email newsletter.